FDA: “Rational” expansion of eligibility criteria for clinical trials would accelerate drug development April 21, 2017Vol.43 No.16
Conversation with The Cancer Letter Huntsman Cancer Foundation: “We are asking the University of Utah to reinstate Dr. Beckerle” April 21, 2017Vol.43 No.16By Paul Goldberg
Conversation with The Cancer Letter Huntsman: “Dr. Beckerle will be back in a few weeks.” April 21, 2017Vol.43 No.16By Paul Goldberg
Beckerle ousted at Huntsman Cancer Institute as University of Utah asserts control over center’s funds;Founder Jon Huntsman declares war on university leaders April 21, 2017Vol.43 No.16By Paul Goldberg
ASCO says “right-to-try” laws don’t safeguard patients and fail to address problems in obtaining therapies April 14, 2017Vol.43 No.15By Paul Goldberg
U.S. cancer costs add up to $87.8 billion; Patients pay $4 billion out-of-pocket April 14, 2017Vol.43 No.15
Permanent advisory board needed to combat scientific misconduct, NAS report recommends April 14, 2017Vol.43 No.15By Paul Goldberg
Guest Editorial How not to develop a medical intervention: Learning from the prostate screening debacle April 14, 2017Vol.43 No.15By Otis W. Brawley
Conversation with The Cancer Letter Doug Ulman: MD Anderson trademark lawsuit is a frustrating “distraction from our core mission” April 14, 2017Vol.43 No.15By Matthew Bin Han Ong
